SUNITINIB MALATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · RENAL CELL CARCINOMA ·+3
NOVADOZ PHARMAC
Drug class
Protein Kinase Inhibitors for Renal Cell Carcinoma
Protein kinase inhibitors for renal cell carcinoma represent a targeted therapeutic drug class consisting primarily of small-molecule receptor tyrosine kinase inhibitors. Read more about Protein Kinase Inhibitors for Renal Cell Carcinoma
60 drugs in this class 38 manufacturers
Drugs in Protein Kinase Inhibitors for Renal Cell Carcinoma
AFINITOR (everolimus)
ANTINEOPLASTIC - MTOR KINASE INHIBITORS · METASTATIC RENAL CELL CARCINOMA ·+6
Novartis Pharmaceuticals
AFINITOR DISPERZ (everolimus)
ANTINEOPLASTIC - MTOR KINASE INHIBITORS · SUBEPENDYMAL GIANT CELL ASTROCYTOMA ASSOCIATED WITH TUBEROUS SCLEROSIS ·+1
Novartis Pharmaceuticals
VOTRIENT (pazopanib HCl)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SOFT OR CONNECTIVE TISSUE SARCOMA ·+1
Novartis Pharmaceuticals
EVEROLIMUS
ANTINEOPLASTIC - MTOR KINASE INHIBITORS · METASTATIC RENAL CELL CARCINOMA ·+6
NOVUGEN PHARMA
YULITHIRA (everolimus)
ANTINEOPLASTIC - MTOR KINASE INHIBITORS · METASTATIC RENAL CELL CARCINOMA ·+6
CIVICASCRIPT, L
Filter & compare in the drug finder →
Opens the drug finder with Protein Kinase Inhibitors for Renal Cell Carcinoma preselected. Add indication or manufacturer filters there.
Protein kinase inhibitors for renal cell carcinoma represent a targeted therapeutic drug class consisting primarily of small-molecule receptor tyrosine kinase inhibitors.
These agents work principally by inhibiting vascular endothelial growth factor receptors, along with other key kinase pathways such as platelet-derived growth factor receptor, MET, and AXL.
By disrupting these downstream intracellular signaling cascades, they impair tumor-associated angiogenesis, cellular proliferation, and metastasis.
The primary clinical indication for this class is advanced or metastatic renal cell carcinoma, where these drugs are utilized as monotherapy or combined with immune checkpoint inhibitors, and they may also offer therapeutic utility across other vascularized malignancies.
-
nih.gov
Protein kinase inhibitors for renal cell carcinoma represent a targeted therapeutic drug class consisting primarily of small-molecule receptor tyrosine kinase inhibitors These agents work principally by inhibiting vascular endothelial growth factor receptors, along with other key kinase pathways such as platelet-derived growth factor receptor, MET, and AXL By disrupting these downstream intracellular signaling cascades, they impair tumor-associated angiogenesis, cellular proliferation, and metas...
-
nih.gov
Protein kinase inhibitors for renal cell carcinoma represent a targeted therapeutic drug class consisting primarily of small-molecule receptor tyrosine kinase inhibitors
-
researchgate.net
These agents work principally by inhibiting vascular endothelial growth factor receptors, along with other key kinase pathways such as platelet-derived growth factor receptor, MET, and AXL
-
nih.gov
The primary clinical indication for this class is advanced or metastatic renal cell carcinoma, where these drugs are utilized as monotherapy or combined with immune checkpoint inhibitors, and they may also offer therapeutic utility across other vascularized malignancies
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.